Charles River Laboratories, a Wilmington, Massachusetts-based drug research company, has signed an agreement to acquire a Chinese pharmaceutical contractor for about $1.6 billion. Charles River is acquiring WuXi AppTec, a Chinese pharmaceutical outsourcing services provider.